Skip to main content

Antipyrine/benzocaine/phenylephrine otic Disease Interactions

There are 5 disease interactions with antipyrine / benzocaine / phenylephrine otic.

Major

Otic agents (applies to antipyrine/benzocaine/phenylephrine otic) perforated tympanic membrane

Major Potential Hazard, High plausibility. Applicable conditions: Chronic Otitis Media, Chronic Otitis Media

The use of medications that are intended for the treatment of otitis externa or other conditions of the external ear canal should generally be avoided, or otherwise approached with caution, in patients with a perforated tympanic membrane due to the risk of toxicity from medication that may get into the middle ear. Caution is also advised in patients with longstanding, chronic otitis media because of the possibility of a perforated tympanic membrane in such patients.

References (2)
  1. "Multum Information Services, Inc. Expert Review Panel"
  2. Arvin A, Kliegman R, Nelson W, Behrman R, eds. (1996) "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company
Moderate

Benzocaine (applies to antipyrine/benzocaine/phenylephrine otic) methemoglobinemia

Moderate Potential Hazard, Low plausibility. Applicable conditions: G-6-PD Deficiency

Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis. Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia. If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.

References (2)
  1. (2001) "Product Information. Americaine (benzocaine topical)." Novartis Consumer Health
  2. (2001) "Product Information. Americaine Otic (benzocaine otic)." Medeva Pharmaceuticals
Moderate

Topical phenylephrine (applies to antipyrine/benzocaine/phenylephrine otic) cardiovascular

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Cerebrovascular Insufficiency, Hyperthyroidism

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

References (4)
  1. Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
  2. Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
  3. (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
  4. (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
Moderate

Topical sympathomimetics (applies to antipyrine/benzocaine/phenylephrine otic) BPH

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Benign Prostatic Hyperplasia, Prostate Tumor

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

References (14)
  1. Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
  2. Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
  6. (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
  7. (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
  8. (2001) "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough
  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
  10. (2001) "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health
  11. (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
  13. (2001) "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc
  14. (2001) "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc
Moderate

Topical sympathomimetics (applies to antipyrine/benzocaine/phenylephrine otic) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

References (14)
  1. Lansche RK (1966) "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol, 61, p. 95-8
  2. Ellis PP (1971) "Systemic reactions to topical therapy." Int Ophthalmol Clin, 11, p. 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc
  6. (2001) "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough
  7. (2001) "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals
  8. (2001) "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough
  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
  10. (2001) "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health
  11. (2001) "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
  13. (2001) "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc
  14. (2001) "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc

Switch to consumer interaction data

Antipyrine/benzocaine/phenylephrine otic drug interactions

There are 2 drug interactions with antipyrine / benzocaine / phenylephrine otic.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.